The 17th Annual Meeting on Surveillance, Preparedness and Response to Meningitis Outbreaks in Africa and the seventh meeting of MenAfriNet Partners was hosted virtually by Chad. Several topics, including risk assessments and mitigation strategies, were discussed and action items established in an effort to defeat bacterial meningitis by 2030- an initiative adopted by multiple organizations during...
The story of Rahinatou, a young meningitis survivor from Niger, highlights the importance of rapid care, high quality surveillance, and strong laboratory capacities in reducing the burden of bacterial meningitis across Nigerien communities.
Professor Rasmata Ouédraogo-Traoré, the Chief of the Medical Analysis Laboratory of the Charles De Gaulle Pediatric Hospital, which houses the National Reference Laboratory for meningitis in Burkina Faso, shares her journey to this career while outlining the importance of laboratories and scientific studies in the fight against bacterial meningitis.
Meningitis outbreaks due to the type of bacterial called Neisseria Meningitidis A are decreasing due to vaccinations with an exciting new vaccine called MenAfriVac. This was made possible through a strong partnership aimed at reducing the burden of bacterial meningitis so that survivors like Payan, who’s story is shared here, are better protected from the deadly disease in the future.
Dr. Isaïe Medah, director general of public health, shares his experiences and successes in reaching high vaccine coverage with a serogroup A meningococcal conjugate vaccine (MenAfriVac®, MACV) through highly collaborative partnership efforts and community education.